Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Summary not available.
ZOLL Medical Corporation has announced a definitive agreement to acquire Itamar Medical Ltd. for approximately $538 million. This acquisition will enable ZOLL to enhance its services for undiagnosed cardiac patients suffering from sleep apnea. Itamar’s WatchPAT device, which is FDA-cleared, is a key component in this integration to improve diagnosis and treatment in the cardiopulmonary sector. The deal represents a premium of 50.2% over Itamar's stock price on September 10, 2021, and is expected to close by the end of 2021.